Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aera Therapeutics Names Paul Conrad Chief Business & Financial Officer

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Aera Therapeutics Appoints Paul Conrad Chief Business and Financial Officer

Dr. Conrad brings over 30 years of experience spanning R&D, strategy and operations, business and corporate development, alliance management, and finance.

By: Rachel Klemovitch

Assistant Editor

Aera Therapeutics, a biotechnology company, announced the appointment of Paul Conrad, Ph.D., MBA, as chief business and financial officer. 

Dr. Conrad brings over 30 years of biopharma experience and expertise spanning R&D, strategy and operations, business and corporate development, alliance management, and finance.

Akin Akinc, Ph.D., chief executive officer of Aera, said, “Paul is a seasoned biopharmaceutical executive, and his leadership will be key as we continue to build the company, advance our programs toward the clinic, and develop enabling delivery technologies to expand the application and impact of genetic medicines.”

Dr. Conrad began his career as a biochemical engineer at Merck & Co. Before Aera, Dr. Conrad served as chief business officer at NextPoint Therapeutics. There, he established research partnerships, secured multiple rounds of financing, and built out the company’s operations. 

Previously, he served as vice president and head of business development, alliance management, and pipeline strategy at bluebird bio. He played a pivotal role in expanding the company’s oncology cell therapy pipeline. 

Before bluebird, Dr. Conrad held business and corporate development roles at Shire, Baxalta, and AMAG Pharmaceuticals.

“With a clear focus on next-generation delivery technologies, Aera is well-positioned to impact the landscape of genetic medicines by broadening their application across many patient populations and disease areas,” said Dr. Conrad. “I am excited to be a part of Aera’s exceptional team and look forward to contributing to the next chapter of growth for the company.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters